Recent Updates
Recently added Catalysts
BBIO Positive Sentiment Score: 70/100

BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week

Friday, October 24, 2025 1 min read
Key Takeaway: BridgeBio Pharma, Inc. will host business update calls to report results from the FORTIFY Phase 3 study for its small molecule BBP-418 targeting Limb-girdle Muscular Dystrophy Type 2I/R9. The interim analysis results webinar is scheduled for October 27, followed by the Q3 2025 earnings report on October 29. These events highlight the company's ongoing commitment to addressing genetic diseases and keeping stakeholders informed.

Market Sentiment Analysis

POSITIVE FACTORS

  • Upcoming Phase 3 results for BBP-418 may show promising efficacy.
  • BridgeBio is actively engaging with the investment community through earnings calls.
  • Focus on genetic diseases positions BridgeBio in a growing sector.

Full Press Release Details

PALO ALTO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host two separate business update calls to share the following:
Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) FORTIFY Phase 3 Interim Analysis Topline Results Webinar: Monday, October 27 at 8:00 am ET
Q3 2025 Earnings: Wednesday, October 29 at 4:30 pm ET
To access the live webcast for BridgeBio's calls, please visit the “Events and Presentations” page within the Investors section of the BridgeBio website at https://investor.bridgebio.com. A replay of the webcasts will be available on the BridgeBio website for 90 days following the event.
About BridgeBio Pharma, Inc.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
contact@bridgebio.com
BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance

Frequently Asked Questions

When is the LGMD2I/R9 FORTIFY Phase 3 update call?

The LGMD2I/R9 FORTIFY Phase 3 update call is on October 27 at 8:00 am ET.

What date is BridgeBio's Q3 2025 earnings call?

BridgeBio's Q3 2025 earnings call is scheduled for October 29 at 4:30 pm ET.

How can I access BridgeBio's business update calls?

You can access the calls via the 'Events and Presentations' page on BridgeBio's website.

Will the webcasts be available after the live events?

Yes, the webcasts will be available for replay on the website for 90 days.

Tags: BBIO Viatris Investor Conferences Healthcare BridgeBio BBP-418 LGMD2I/R9 Phase 3 biopharmaceutical
Last updated: Oct 24, 2025